Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports (Q33402749)

26 July 2017

Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports (English)

1 reference

thrombotic thrombocytopenic purpura

26 July 2017

1 reference

1 reference

1 reference

Futoshi Iioka

1

1 reference

26 July 2017

Daiki Shimomura

2

1 reference

26 July 2017

Toru Ishii

3

1 reference

26 July 2017

Yoshitomo Maesako

4

1 reference

26 July 2017

Kazuhiro Ohgoe

5

1 reference

26 July 2017

Fumihiko Nakamura

6

1 reference

26 July 2017

Shuji Matsuo

7

1 reference

26 July 2017

Hitoshi Ohno

8

1 reference

26 July 2017

10 August 2012

1 reference

International Journal of Hematology

26 July 2017

1 reference

26 July 2017

96

1 reference

26 July 2017

4

1 reference

26 July 2017

506-512

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-012-1162-2

26 July 2017

0 references

cites work

Clinical practice. Thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

How I treat patients with thrombotic thrombocytopenic purpura: 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Rituximab in the treatment of autoimmune haematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Plasma levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity LevEls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Survival and relapse in patients with thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1162-2

Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22878941

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22878941

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22878941

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12185-012-1162-2

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference